Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab-associated RCCEP and efficacy in advanced non-squamous NSCLC
ChiCTR2100043702Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100043702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043702.